LOOSEN PharmaBio SRL
LOOSEN PharmaBio reported total assets of 335,194 € at the end of the 2025 financial year (annual accounts filed with the NBB on 17 Jun 2026).
The score of LOOSEN PharmaBio shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -51 % Total assets +30 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
LOOSEN PharmaBio's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 132,162 € | ||||
| Equity | 20,965 € | ||||
| Cash | 202,164 € | ||||
| EBITDA | 187,766 € | ||||
| Total assets | 335,194 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 17 Jun 2026
- Year ended 31 Dec 2024filed on 07 Jul 2025
- Year ended 31 Dec 2023filed on 06 Jul 2024
- Year ended 31 Dec 2022filed on 06 Jul 2023
- Year ended 31 Dec 2021filed on 19 Jul 2022
LOOSEN PharmaBio's financial analysis
- Solvency6.3%sector median: 66.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of LOOSEN PharmaBio
LOOSEN PharmaBio's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0563.958.196
- VAT number
- BE0563958196
- Peppol
- Registered · 0208:0563958196 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 14 Oct 2014
- Registered office
- 1430 Rebecq
- Latest accounts
- 2025 · filed on 17 Jun 2026
- Activity
- Diagnostic imaging services and medical laboratory activities (NACE 86910)
LOOSEN PharmaBio (SRL) has been based in Rebecq since 2014, active in: diagnostic imaging services and medical laboratory activities. For 2025, it reports a net profit of 132,162 € and equity of 20,965 €; its revenue is not published. Its solvency stands at 6.3%, below the median of its sector (66.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to LOOSEN PharmaBio
Companies in the same business, of comparable size and area, outside its group.
- Flash-Invest Boom · balance sheet 335,064 €
- Mediavision-Imagimage Motion picture and video distribution activities Waterloo · balance sheet 334,869 €
- Leclof Uccle · balance sheet 335,530 €
- A.B. Dental Smile Dental practice care activities Huy · balance sheet 335,192 €
- Preventia Activities of agents involved in the wholesale of textiles, clothing, fur, footwear and leather goods Ronse · balance sheet 335,164 €
Frequently asked questions about LOOSEN PharmaBio
What is the revenue of LOOSEN PharmaBio?
LOOSEN PharmaBio files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of LOOSEN PharmaBio?
In Belgium, the VAT number is the company number prefixed with BE: BE0563958196 for LOOSEN PharmaBio, if the company is VAT-registered. Its company number (CBE) is 0563.958.196.
Where is the registered office of LOOSEN PharmaBio?
According to the CBE register, the registered office of LOOSEN PharmaBio is in 1430 Rebecq.
What is the equity of LOOSEN PharmaBio?
At the close of the 2025 financial year, the equity of LOOSEN PharmaBio amounts to 20,965 €, a solvency of 6.3% of total assets.
Who manages LOOSEN PharmaBio?
The register lists 1 active mandates at LOOSEN PharmaBio. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of LOOSEN PharmaBio
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →